Abstract | BACKGROUND: METHODS: Within a single-centre cohort of patients with biopsy confirmed AL-amyloidosis diagnosed between January 1995 and December 2012, we aimed to investigate treatment effects in patients treated with conventional chemotherapy versus HDCT with ASCT. RESULTS: We identified 50 patients with AL-amyloidosis treated with conventional chemotherapy and 13 patients who received HDCT with ASCT. Clinical characteristics differed between the groups for the age of the patients (59 years for patients with ASCT/HDCT vs 69 years; p= 0.0006) and the troponin-T value (0.015 μg/l vs 0.08 μg/l; p = 0.0279). Patients with ASCT showed a trend towards better overall survival, with median survival not yet reached compared with 53 months in patients on conventional chemotherapy (p = 0.0651). CONCLUSION: Our results suggest that light chain AL-amyloidosis patients considered fit to undergo HDCT and ASCT may have a better outcome than patients treated exclusively with conventional chemotherapy regimens; however, the better performance status of patients receiving HDCT may have added to this treatment effect.
|
Authors | Joëlle Raschle, Yara Banz, Thomas Suter, Thomas Pabst |
Journal | Swiss medical weekly
(Swiss Med Wkly)
Vol. 144
Pg. w13922
(Feb 19 2014)
ISSN: 1424-3997 [Electronic] Switzerland |
PMID | 24554372
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Age Factors
- Aged
- Aged, 80 and over
- Amyloidosis
(blood, therapy)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Combined Modality Therapy
(methods)
- Disease Progression
- Female
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Retrospective Studies
- Stem Cell Transplantation
- Transplantation, Autologous
- Troponin T
(blood)
|